Drug Search Results
More Filters [+]

Indoximod

Alternative Names: indoximod, 1-methyl-d-tryptophan, NLG8189, NLG 8189, NLG-8189, D-1MT
Latest Update: 2024-08-30
Latest Update Note: Clinical Trial Update

Product Description

A methylated tryptophan with immune checkpoint inhibitory activity. Indoximod inhibits the enzyme indoleamine 2,3-dioxygenase (IDO), which degrades the essential amino acid tryptophan, and may increase or maintain tryptophan levels important to T cell function. Tryptophan depletion is associated with immunosuppression involving T cell arrest and anergy. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/indoximod)

Mechanisms of Action: IDO1 Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Lumos Pharma
Company Location: AUSTIN TX 78756
Company CEO: Richard J. Hawkins
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Indoximod

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Melanoma

Phase 2: Ependymoma|Glioblastoma|Glioma|Male Breast Cancer|Medulloblastoma|Prostate Cancer|Breast Cancer|Melanoma

Phase 1: Glioma|Kidney Diseases|Ependymoma|Gliosarcoma|Acute Myeloid Leukemia|Medulloblastoma|Glioblastoma|Brain Cancer|Healthy Volunteers|Lung Cancer|Melanoma|Pancreatic Cancer|Non-Small-Cell Lung Cancer|Breast Cancer|Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

GCC2020

P1

Recruiting

Ependymoma|Brain Cancer|Medulloblastoma|Glioblastoma

2026-08-01

GCC1949

P2

Recruiting

Medulloblastoma|Glioblastoma|Ependymoma|Glioma

2025-10-02

2014-003540-12

P2

Terminated

Breast Cancer

2022-05-04

2017-003634-93

P3

Unknown status

Melanoma

2021-11-28

Recent News Events